OptiNose, Inc. (NASDAQ:OPTN) Shares Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC raised its stake in OptiNose, Inc. (NASDAQ:OPTN) by 142.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,688,590 shares of the company’s stock after buying an additional 3,338,580 shares during the quarter. OptiNose comprises about 2.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 13th biggest holding. Stonepine Capital Management LLC owned about 3.77% of OptiNose worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of OPTN. GSA Capital Partners LLP acquired a new position in OptiNose in the third quarter valued at about $61,000. XTX Topco Ltd acquired a new position in OptiNose in the second quarter valued at about $88,000. Squarepoint Ops LLC lifted its position in OptiNose by 173.7% in the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock valued at $178,000 after buying an additional 108,903 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in OptiNose by 15.4% during the third quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock worth $764,000 after purchasing an additional 152,435 shares during the period. Finally, Easterly Investment Partners LLC increased its stake in OptiNose by 5.0% during the third quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock worth $1,581,000 after purchasing an additional 113,015 shares during the period. Institutional investors and hedge funds own 85.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on OPTN shares. Piper Sandler cut their price target on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of OptiNose in a research note on Wednesday, November 13th.

OptiNose Price Performance

Shares of OPTN stock traded up $0.01 during trading hours on Wednesday, reaching $0.53. 98,945 shares of the stock were exchanged, compared to its average volume of 773,250. The business’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.92. OptiNose, Inc. has a 12-month low of $0.32 and a 12-month high of $2.10. The firm has a market capitalization of $79.67 million, a P/E ratio of -1.83 and a beta of -0.07.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.